OSI Pharmaceuticals (OSIP) - formerly Oncogene Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (276)	10/10/2005 9:33:51 PM
From: DewDiligence_on_SI	Read Replies (1) of 447

I can find no information on Lucentis being developed for anything other than AMD. It’s just a matter of time—a drug that is safe and effective in wet AMD is more than likely going to work in DME too. If Lucentis is approved for AMD, it ought to garner good off-label penetration in DME from the get-go. -- The recent OSIP price drop has made me consider buying back in. However, I think I’ll wait for the release of the Lucentis ANCHOR data, which are expected soon. Goddard has based his evaluation of Macugen—at least in part—on the notion that Lucentis may not work as well in predominantly-classic AMD as it does in minimally-classic/occult AMD. The ANCHOR data may blow this idea out of the water.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next